| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
HRD
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Niraparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Niraparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
HRD
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Rucaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Rucaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Rucaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Rucaparib
|
|
| Sensitivity (+) |
FOLR1 positive
|
High-Grade Serous Fallopian Tube Cancer |
Mirvetuximab soravtansine
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
HRD
|
High-Grade Serous Fallopian Tube Cancer |
Bevacizumab,
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA1 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 oncogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|
| Sensitivity (+) |
BRCA2 pathogenic variants
|
High-Grade Serous Fallopian Tube Cancer |
Olaparib
|
|